Abstract. Lymphocyte attachment to fibronectin is mainly mediated by the interaction of ix5/31 and ot4/31 integrins with the RGD and CS-1/Hep II sites, respectively. We have recently shown that the anti-/31 mAb TS2/16 can convert the partly active a4B1 present on certain hemopoietic cells that recognizes CS-1 but not Hep II, to a high avidity form that binds both ligands. In this report we have studied whether mAb TS2/16 also affects ot4B1 ligand specificity. Incubation of the B cell lines Ramos and Daudi (which lack ix5/31) with mAb TS2/16 induced specific attachment to an 80-kD fragment which lacks CS-1 and Hep II and contains the RGD sequence, mAbs anti-oM and the synthetic peptides CS-1 and IDAPS inhibited adhesion to the 80-kD fragment thus implying ol4/31 as the receptor for this fragment. Interestingly, the synthetic peptide GRGDSPC and a 15-kD peptic fibronectin fragment containing the RGD sequence also inhibited B cell adhesion to the 80-kD fragment. Because we have previously shown that RGD peptides do not affect the constitutive function of ot4/31, we tested whether TS2/16-aetivated o~4/31 acquired the capacity to recognize RGD. Indeed RGD peptides inhibited TS2/16-treated B cell adhesion to a 38-kD fragment containing CS-1 and Hep II but did not affect binding of untreated ceils to this fragment. An anti-fibronectin mAb reactive with an epitope on or near the RGD sequence also efficiently inhibited cell adhesion to the 80-kD fragment, indicating that the RGD sequence is a novel adhesive ligand for activated ot4/31. These results emphasize the role of ot4/31 as a receptor with different ligand specificities according to the activation state, a fact that may be important for lymphocyte migration, localization, and function.
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YMPHOCYTE interactions with fibronectin (Fn) l are important for their differentiation, migration, activation, and biological function (reviewed in 20, 46) . The specific sequences in Fn that mediate cell attachment are located within two main regions of the molecule: the central cell-binding domain contains the RGD site which acts in synergy with at least two other regions within this domain (56) . The carboxy-terminal region of Fn comprises the Hep II domain and the IIICS region. Within the Hep II domain the following sites have been shown to support melanoma cell adhesion: HI (35) , FNC/H I, and FNC/H II (21, 31) . Two active sites have been identified within IIICS, namely CS-1 (residues 1-25) and CS-5 (residues 90-109) (19) . Both CS-1 and CS-5 are regulated by alternative splicing and are not present in all Fn isoforms. While CS-1 and the entire Hep II domain clearly mediate lymphocyte adhesion to Fn (15, 16, 52) it is not known if these cells recognize the specific sequences contained in H1, FNC/H I, FNC/H II, and CS-5. (44) . The more active form, present on cultured lymphoid cells, was able to bind two fragments of 38 kD (contains CS-1 and Hep II) (13) and 58 kD (contains Hep II) (15) (16) (17) derived from the A and B chains of Fn, respectively. The less active form, present on monocytic cells and peripheral blood T lymphocytes, bound only the 38-kD fragment and thus recognized CS-1 but not Hep II. mAb TS2/16 converted this a4~1 form to a more active one able to recognize both sites. These previous observations therefore indicate that there are cell populations which constitutively express a low or intermediate avidity a4/$1 form unable to recognize some of its ligands. In view of these results it was conceivable that activation of the receptor would lead to the recognition of new low affinity ligands not previously identified.
In the present report we have studied whether ot4/~1 activation via the/31 subunlt affects the ligand specificity of this receptor. We show that o~5/~l-negative B lymphoid cells that do not bind constitutively to the 80-kD Fn fragment, efficiently attach to this fragment upon incubation with mAb TS2/16. We have identified the t~4/$1 integrin as the receptor that mediates adhesion to the 80-kD fragment and we show that the RGD sequence in Fn is a novel ligand for activated .4~1.
Materials and Methods

ECM Proteins, Fragments, and Synthetic Peptides
Human plasma Fn was the generous gi~ of Drs. B. Horowitz and R. Shulman (New York Blood Center, New York). Fragments of 80, 58, 38, 31, and 29 kD (see Fig. 1 ) were obtained from tryptic digestions of Fn and purified exactiy as previously described (13) (14) (15) . Purity of the 80-kD fragment was assessed by SDS-PAGE, Western blots, ELISA, and NH2-terminal amino acid sequencing. Amino acid sequence analyses were performed by Mr. Javier Varela at the Protein Chemistry Laboratory, Centro de Investigaciones Biol6gicas (Madrid, Spain), using a 477A liquid-phase sequencer (Applied Biosystems, Inc., Foster City, CA). The 80-kD fragment was cleaved with pepsin (1:100 wt/wt, 37"C, 1 h) as described (40) . Peptic digests were resolved by fast protein liquid chromatography (Pharmacia LKB Biotechnology, Uppsala, Sweden) using a Mono Q ion exchange column (Phannacia LKB Biotechnology) equilibrated in 10 mM Tris pH 7.0, buffer (A). Bound fragments were eluted by applying a 45-min gradient from 100% A to 40% A-60% B (10 mM Tris, 500 mM NaC1, pH 7.0). Characterization of peptic fragments was achieved by SDS-PAGE, Western blots, ELISA, and NH2-terminal amino acid sequencing. Purified fragments were dialyzed versus PBS and stored at -70°C. The following synthetic peptides were purchased from Bio-Synthesis D&I (Madrid, Spain): GRGDSPC and GRGES, containing sequences from the central cell-binding domain; DELPQLVTLPHPNLHGPEILDVPSTC (CS-1), PSTVQKTPF-VTHPGYDTGNGIQLPG (CS-2), and, CIQLPGTSGQQPSVGQQMIF-EEHGFR (CS-3), containing sequences from the I]ICS region, and IDAPS containing an active sequence present in the Hep II domain (35) . Laminin and collagen type I were purchased from Sigma Chemical Co. (Saint Louis, MO).
Monoclonal Antibodies
Fn-specific mAbs P1Fll (anti-CS-1) and P3D4 (anti-Hep II domain) were produced as reported (17) . mAbs N-295 and N-296 were originally purchased from Mallinckrodt Specialty Chemicals (Maryland Heights, MO) and are now available through Chemic.on International, Inc. (MABI934 and MAB1935, respectively; Temecula, CA). mAb N-295 reacts with the 11-kD fragment that contains the RGD sequence of fibronectin (40) and partially inhibits cell adhesion (32) . mAb N-296 reacts with a carboxy-terminal fragment that contains the Fib II domain and does not affect cell adhesion (32) . mAbs to the ct4 integrin subtmit HP1/1 (epitope A), HP2/1 (epitope B1), and mAbs Alex 1/4 and TS2/16 specific for the/51 subunit were obtained from Dr. E S(mchez-Madrid (Hospital de la Princesa, Madrid, Spain). mAbs P1D6 (anti-a5) and P1B5 (anti-c~3) were obtained from Dr. E. A.
Wayner (University of Minnesota, Minneapolis, MN). mAb LM609 (antitAr~3) was obtained from Dr. D. Cheresh (Scripps Clinic, San Diego, CA). mAb IIF5 (anti-a3) was obtained from Dr. M. Hemier (Dana Farber Cancer Institute, Boston, MA). mAb D3/9 (anti-CD45) was obtained from Dr. C. Bernabeu (Centro de Investigaciones Bitlogicas, Madrid, Spain).
Cells and Cell Culture
The human cell lines Daudi, RPM18866, JY (B lymphoblastoid), and K562 (erythroleukemia) were obtained from Drs. E Sfmchez-Madrid and C. Bernabeu. The melanoma cell line A375 was obtained from Dr. J. Teixid6 (Centro de Investigaciones Biol6gicas). The B cell line Ramos and the monocytic cell line U937 were obtained from the American Type Culture Collection (Rackville, MD). Cells were expanded in RPMI 1640, supplemented with 10% hot-inactivated fetal bovine serum (Gibco, Middlesex, UK), 2 mM L-glutamine, 100 U/ml penicillin (Antibi6ticos, Madrid, Spain), and 24 #f/nil gentamycin (Llorente, Madrid, Spain). In general, three/four-day cultures were used for assays.
Cell Attachment Assays
These assays were performed exactly as described (44) using flat bottom, high binding, 96-well plates (Costar Corp., Cambridge, MA). Quantitation of cell attachment was done by determining the absorbance at 620 um on a Multiskan Bichromatic plate reader (Labsystems, Helsinki, Finland) and using calibration curves as described (44) . Integrin activation through the /31 subunit was performed by incubating the cells with a I:10 dilution of supernatant containing anti-/~l rnAbs for 15-20 rain at 37°C prior to the attachment assay. For inhibition experiments cells were incubated with antiintegrin antibodies (15 rain, 37°C) or synthetic peptides or fragments (30 rain, room temperature) prior to adding to substrate-coated wells. Inhibition of cellular attachment by antibodies to Fn was determined after incubation of 80-or 38-kD-coated wells with 50 #1 of appropriate antibody dilutions for 30 rain at room temperature; 50 #1 of cell suspension was then added and the assay continued as described above.
Immunofluorescence Analyses
Cells (5 × 105) were incubated for 30 min at 4"C with 100 #1 of culture superuatants (1:2 dilution) or ascites (1:500 dilution) containing the appropilate mAb. Cells were washed twice with cold PBS-I% BSA and resuspended in 100 #1 of a 1/100 dilution of fluorescein-conjugated F(ab')2 fragments of rabbit antibodies to mouse IgG (Dakopatts, Glostrop, Denmark). After 30 min at 4°C cells were washed twice, resuspended in PBS, and analyzed by flow cytometry on an EPICS-CS (Coulter Cientifica, Mdstoles, Spain).
ELISA Assays
These assays were performed as described (17) with the following modifications to improve background: Fn fragments used for coating wells were in 0.1 M sodium borate, pH 8.5 (instead of PBS); plates were washed with 0.1% Tween 20 (instead of 0.05%); incubation with antibodies was done at room temperature (instead of 37°C). Absorbance at 492 um was determined after 10 and 30 rain using a microplate reader.
Results
Fibronectin Fragments That Contain the Central (RGD-dependent) or Carboxy-terminal (RGD-independent) Cell-binding Domains
The Fn tryptic fragments of 38 and 80 kD used in the present study have been previously characterized and are schematically shown in Fig. 1 . The 38-kD fragment, derived from the carboxy-terminal region of the A chain of Fn, conrains the Hep II domain and part of the [LICS region including the CS-1 site (13, 15, 17) . The 80-kD fragment, derived from the central region of both chains of Fn, contains a lowaffinity heparin and DNA-binding domain, the RGD sequence and the RGD-dependent synergistic sites (56) . Both fragments are contiguous in the Fn sequence.
s,. Analysis of the 80-kD fragment rendered the NH2-terfiainal sequence SDVPTS. Further characterization of this fragment was achieved using two recently developed mAbs with specificity for the Hep II (P3IM) and CS-1 (P1Fll) regions, respectively (17) as well as a commercial mAb (N-295) which reacts with a site near the RGD sequence in Fn (32) . As shown in Fig. 2 , using an ELISA assay, mAb N-295 reacted strongly with the 80-kD fragment while mAbs P3D4 and P1F11 were negative. These two mAbs also failed to recognize the 80-kD fragment on Western blots (17) . mAbs P3D4 and P1Fll did react with the 38-kD fragment used as control while mAb N-295 did not (Fig. 2) . Altogether these results clearly show that the 80-kD fragment contains the RGD sequence and that there are no contaminants containing the ct4/31 ligands Hep II and CS-1 in the 80-kD fragment preparation.
Pepsin digestion of the 80-kD fragment rendered two fragments of interest ( Fig. 1 ): a 15-kD fragment that was positive on Western blots and ELISA with mAb N-295 (not shown) and thus contained the RGD sequence. The 15-kD fragment had the NH2-terminal sequence: IGQQ (end of repeat 111-9); a 40/45-kD fragment that rendered two sequences: VLV(R)WTPP (beginning at residue 18 in repeat II1-5) and IQVLRDGQ (end of repeat III-6). The 40/45-kD fragment did not react with mAb N-295 (not shown) and thus did not contain the RGD sequence.
Adhesion of a5f31-negative B Cell Lines to the 80-kD Fn Fragment Following Incubation with Anti-~l mAb TS2/16
The following experiments were undertaken to determine whether mAb TS2/16 affects not only the affinity of the receptor(s) but also its specificity thus resulting in the recognition of novel ligands. To this purpose we performed attachment assays using several Fn fragments not previously shown to support B lymphoid cell adhesion. These include the 80-kD fragment shown in Fig. 1 and two fragments of 29 and 31 kD derived from the amino-and carboxy-terminal regions of Fn, respectively (not shown in Fig. 1 ). The various cell populations used in these studies and their pattern of integrin expression are listed in Table I . As can be observed none of the four B cell lines studied expressed the ct5 integrin subunit on their surface in agreement with previous reports (5, 16, 47) . As shown in Fig. 3 , resting Ramos or Daudi cells or cells incubated with the control anti-~ mAb Alexl/4 did not attach to the 80-kD fragment. However, preincubation of Ramos or Daudi cells with mAb TS2/16 resulted in a doseresponse attachment to the 80-kD fragment (Fig. 3) . Incubation of Ramos cells with mAb TS2/16 always resulted in a more efficient adhesion (60%) to the 80-kD fragment than incubation of Daudi cells (40%), a result consistent with the higher/~1 expression on Ramos cells (Table I) Ramos  35  35  45  95  35  36  113  Daudi  40  ND  39  96 40  43  76  JY  49  48  47  103 46  71  51  RPMI 8866  43  43  42  107 41  61  50  K562  47  ND  45  46  78  56  100  A375  43  89  82  80 68  102  123 the 29-or 31-kD fragments at any of the concentrations tested (not shown).
To confirm the specificity of the effect ofmAb TS2/16 and the involvement of/$1 integrins on the recognition of the 80-kD fragment, we studied the adhesion of the B cell lines JY and RPMI 8866 to this fragment. These cells were chosen because they do not express surface/$1 integrin subunit (Table I and reference 5, 47, 48) . Instead JY and RPMI 8866 cells express an alternative/$ chain called 157, which is associated with the or4 subunit (5, 41). As shown in Fig. 4 , mAb TS2/16 did not induce adhesion of JY or RPMI 8866 cells to the 80-kD fragment. JY cells constitutively attached to the 80-kD fragment and mAb TS2/16 did not affect this constitutive binding (Fig. 4) .
Effect of PMA on Adhesion of B Cells to the 80-kD Fragment: Involvement of Two Different Receptors
To determine whether phorbol myristate acetate (PMA) could reproduce the effect of mAb TS2/16, cells were incubated with 50 ng/ml of PMA for 20 min and tested for adhesion to 80-kD coated wells. As shown in Fig. 4 , PMA did not induce attachment of either Ramos or Daudi cells to the 80-kD fragment while on the same experiment mAb TS2/16 was an effective inducer (Fig. 4) . PMA did not affect either the constitutive adhesion of these ceils to the 38-kD fragment (not shown). In contrast to these results, PMA was an effective activator of JY and RPMI 8866 cells. As shown in Fig. 4 , PMA induced de novo adhesion of RPMI 8866 cells to the 80-kD fragment and increased the constitutive binding of JY cells to this fragment. No changes on integrin surface expression were detected after PMA treatment (not shown).
These results suggested the involvement of two different B cell receptors for the 80-kD fragment, one of them being regulated by mAb TS2/16 and the other by PMA. It was recently demonstrated that the otV/$3 integrin functions as a Fn receptor on some B lymphoid cells (48) . To establish whether oN/$3 was the receptor for the 80-kD fragment on JY and RPMI 8866 cells, we performed attachment assays to this fragment in the presence of anti-oN/s3 mAb LM609. In results not shown, mAb LM609 completely inhibited (100%) the adhesion of resting JY and PMA-treated RPMI 8866 cells to the 80-kD fragment, and partially inhibited (45%) the attachment of PMA-treated JY cells to this fragment. These results therefore confirm the involvement of aV/$3 on adhesion of/$1-negative B cells to the 80-kD fragment and suggest a role for yet another nonidentified receptor on PMA-stimulated JY cells, mAb LM609 had no effect on the adhesion of Ramos or Daudi cells to the 80-kD fragment (Fig. 5) in agreement with the lack of expression of oW/$3 on these cells (Table I) .
Identification of the ~4~31 Integrin as a New Receptor for the 80-kD Fragment
The preceding results clearly indicate that adhesion of Ramos and Daudi cells to the 80-kD fragment is regulated through the/31 subunit. To identify the receptor involved in adhesion to this fragment, cell attachment assays were carried out in the presence of several anti-integrin mAbs. As shown in (anti-o~5), IIF5 (anti-or3), LM609 (anti-oNB3), or the control D3/9 (anti-CD45) had no effect on these assays (Fig. 5) . The effect of the synthetic peptides CS-1 and IDAPS on TS2/16-treated Ramos cell adhesion to the 80-kD fragment was also tested. As shown in Fig. 6 , CS-1 or IDAPS peptides produced a dose-dependent inhibition of cell attachment to the 80-kD fragment, while the control peptides CS-2 ( Fig.  6 ) and CS-3 (not shown) had no effect. Interestingly, the synthetic peptide GRGDSPC was also completely inhibitory in these assays while the control GRGES peptide had no effect (Fig. 6) . The calculated concentration (riM) of peptide required to produce 50 % inhibition of cell attachment to the 80-kD fragment was 5.45 (CS-1, 15/~g/ml), 104 (GRGDS-PC, 80 #g/ml), and 400 (IDAPS, 220/zg/ml). Thus, CS-1 was the most effective inhibitor and the RGD-containing peptide was a better inhibitor than the reported ot4/31 ligand IDAPS.
The RGD Sequence is a Ligand for TS2/16-activated ~4f31 Integrin
The above results therefore suggested that the conformational change induced in a4/31 by mAb TS2/16 results in the ability to recognize the RGD sequence. To prove this, we tested the capacity of the GRGDSPC synthetic peptide to inhibit the adhesion of resting and TS2/16-activated Ramos cells to the 38-kD fragment. As shown in Fig. 7 , resting Ramos cell adhesion to the 38-kD fragment was not affected (90% specific adhesion) by the GRGDSPC peptide (0.5 mg/ml) in agreement with our previous report (16) . However upon incubation with mAb TS2/16, the GRGDSPC peptide (0.5 mg/ml) inhibited cell adhesion to the 38-kD fragment by 50% (Fig. 7) . As expected, the CS-1 peptide used as control was a good inhibitor in both cases. These results clearly show that soluble RGD-containing peptides can effectively inhibit the function of activated o~4/$1 and that activated ot4/~l (but not resting o~4~1) acquires the capacity to recognize the RGD sequence.
As shown in Table II , adhesion of TS2/16-treated Ramos cells to the 80-kD fragment was also inhibited by soluble 80-, 38-, and 15-kD (RGD site) fragments. It was poorly inhibited by the 40/45-kD fragment (no RGD). Direct binding to the 15-kD fragment however could not be demonstrated probably due to the low affinity displayed by this fragment when used as substrate. To further confirm that there was a specific ligand for ot4fll within the 80-kD fragment, we carfled out cell attachment assays in the presence of a panel of anti-Fn mAbs. As shown in Fig. 8 , mAb N-295 which recognizes an epitope near the RGD sequence, inhibited (80%) Ramos cell adhesion to the 80-kD fragment while mAb N-296 (anti-Fib 11) and P3IM (anti-Hep ID had no effect. These results together with the data shown in Fig. 7 , indicate that ot4/~l interaction with the 80-kD fragment is primarily mediated by the RGD sequence. Because inhibition by mAb N-295 was not complete (Fig. 8) , a small contribution from other sites in the 80-kD fragment cannot be completely ruled out.
mAb TS2/16-induced Recognition of New Ligands May Be Specific for Fn and for the ~4f31 Integrin
We next tested whether mAb TS2/16 could induce the recog- tively bound to the 80-kD fragment and showed low constitutive binding to laminin and collagen. Preincubation with mAb TS2/16 effectively increased A375 cell adhesion to all three substrata (Fig. 9 ) in agreement with previous reports (1, 2) . This effect was not due to cross-linking of cells to ECM proteins via the TS2/16 antibody because in control experiments mAb TS2/16 did not bind to either Fn, laminin, or collagen (results not shown). Increased adhesion of A375 cells to ECM proteins was rather due to the upregulation of et5E1, ot2/~l, and ot6E1 integrins which are receptors for the 80-kD Fn fragment, collagen, and laminin, respectively (1, 2, 6). As expected, RPMI 8866 and JY cells, which lack/~1, did not bind to laminin or collagen in response to incubation with mAb TS2/16 (not shown).
To determine whether the effect of mAb TS2/16 on ot4E1 was also observed on other integrins such as ot5E1, K562 cells were incubated with this rnAb and tested for adhesion to the 38-kD fragment. K562 ceils do not express ot4E1 (Table I) and consequently they do not bind to the 38-kD fragment constitutively, mAb TS2/16 did not induce adhesion of K562 cells to the 38-kD fragment although this mAb effectively enhanced their constitutive binding to the 80-kD fragment via ~5E1 (results not shown). Thus the capacity to recognize new ligands upon activation via E1 may be an intrinsic property of the ot4~l integrin.
nition of other extracellular matrix (ECM) proteins not previously known to interact with ct4fll. To this purpose, we performed cell attachment assays using collagen and laminin as substrata. These two proteins are known ligands for other E1 integrins including ct2E1, a3E1, and o~6E1 (20) . As shown in Fig. 9 , incubation of Ramos cells with mAb TS2/16 did not result in adhesion to either laminin or collagen. Because ot4E1 is the main integrin expressed on Ramos cells (Table  I) these results indicate that mAb TS2/16 does not induce ot4Bl recognition of laminin or collagen. To confirm that it was enough substrata on the plates to support cell attachment we used the melanoma cell line A375 as control. A375 cells express several E1 integrins (Table I) including the laminin receptor ct6B1 (1) . As shown in Fig. 9 , A375 cells constitu- Figure 9 . Effect ofmAb TS2/16 on cell adhesion to laminin and collagen type I. Ramos or control A375 melanoma cells were incubated with mAb TS2/16 prior to adding to 80 kD (38 #g/ml), laminin (LM, 150 #g/ml), or type I collagen (COL, 150 ttg/ml) coated wells. After 30 min at 37°C attached cells were quantitated as described. Values on the ordinate represent the number of attached cells relative to the total cell input (5 × liT/well) and are the means of two different experiments.
Discussion
The major conclusions of this report are: (a) ot5El-negative human B lymphoid cells, which do not bind constitutively to the 80-kD fragment of Fn, acquire the capacity to attach to this fragment upon incubation with anti-~ mAb TS2/16; (b) the B lymphoid cell receptor that interacts with the 80-kD fragment is the oL4E1 integrin; (c) the RGDS sequence is a ligand for TS2/16-activated o~4E1 integrin, this indicates that the conformational change induced on ot4/~l by mAb TS2/16 results in the ability to recognize RGD; and (d) a4E1 on B lymphoid cells can be induced to recognize novel ligands in Fn but not in laminin or type I collagen.
Our previous work has definitely established that some B lymphoid cells do not express the ot5E1 integrin and are unable to attach to the 80-kD fragment containing the RGD site (16) . In the present study we show that incubation of the ct5El-negative B cell lines Ramos and Daudi with anti-/~l mAb TS2/16 results in an efficient and specific attachment to the 80-kD fragment. Our results clearly show that adhesion of B cells to the 80-kD fragment is mediated by the ot4E1 integrin. This was demonstrated by the ability of mAbs anti-or4 and the synthetic peptides CS-1 and IDAPS to inhibit cell attachment to the 80-kD fragment. Interestingly, the GRGDSPC synthetic peptide was also a good inhibitor of TS2/16-treated a4/~l function. We have conclusively shown in previous work that the interaction of ot4~l with its ligands, the 38-and 58-kD Fn fragments, is not affected by RGDcontaining peptides (12, 15, 16, 52) . Consistent with this Ramos (untreated or treated with a control mAb) cell attachment to the 38-kD fragment was not affected by the GRGDSPC peptide (this report, Fig. 7 ). As shown in the present studies, the RGD sequence not only inhibited TS2/ 16-treated 0~4/31 function in soluble form but was also the primary site that mediated attachment to the 80-kD fragment, as suggested by the good inhibition attained by N-295 mAb. However the contribution of other regions of the 80-kD which may act synergistically with RGD cannot be completely disregarded.
In a previous report (34) Mould et al., showed that oL4/31-mediated spreading of melanoma ceils can be inhibited by RGD synthetic peptides and that these peptides may elute the ot4/31 integrin complex from a CS-I affinity column. In contrust with these findings, we did not observe ot4/31 recognition of RGD-synthetic peptides unless previous incubation of B cells with mAb TS2/16. Although we cannot explain this discrepancy with the available data, it should be considered that a direct comparison between the work by Mould et al., and ours is difficult because of the different cell types and phenomena studied (spreading versus adhesion). Alternatively, it is possible that the melanoma cells used in reference 34 bear a constitutively activated form of ct4/31 sensitive to RGD-containing peptides.
Several studies have shown that certain anti-/31 mAbs enhance the function of some/31 integrins by inducing a conformational change which results in an activated form of the receptor with higher avidity/affinity for its ligands (1, 27, 49, 53) . The activated form of the receptor may display broader ligand specificity than the resting form. For example, ot2/31 is a collagen receptor on platelets and fibroblasts and a collagen and laminin receptor on other cell types (8, 23, 29) . A recent report has shown that, on the same cell, mAb TS2/16 can convert the partly active form of ot2/31 which recognizes only collagen to a fully active form that also binds laminin (6) .
We and others have recently shown that o~4/31 also exists in several states of activation among different hemopoietic cells. Monocytic cells and PBL bear a partly active form of ot4/31 which recognizes CS-1 but not Hep II; mAb TS2/16 converted ot4/31 to a more active form (constitutively present on cultured lymphoid cells) able to recognize both ligands in Fn (44) . In another study that compares the binding to CS-1 and vascular cell adhesion molecule-1 (VCAM-1), the less active form of u4/31 bound only VCAM-1 while the TS2/16-activated form bound VCAM-1 and CS-1 (30) . The phorbol ester PMA can also activate o~4/31 on U937 ceils or PBL (44) . It is interesting that in the present studies PMA did not induce Ramos or Daudi cell attachment to the 80-kD fragment. PMA did not enhance either the constitutive binding of these cells to the 38-kD fragment thus suggesting that the ot4/31 form present on Ramos and Daudi cells cannot be further activated by phorbol esters. A different regulation of ot4/31 function by anti-/31 mAbs and Ca 2÷ has already been observed (30) . It has also been reported that PMA has no (or minimal) effect on the binding of c~2/31 to collagen or laminin while mAb TS2/16 was highly stimulatory (6) . The fact that mAb TS2/16 can also activate solubilized/31 integrins (2, 6) is in accordance with the lack of requirement for an intraceilular activation pathway. These observations support the existence of distinct mechanistic ways of regulating integrin function. Because PMA does increase c~4/31 function on some cells, it is possible that the sensitivity to a particular stimulus is determined by the activation state of the integrin or by the cell type or both.
These previous studies have analyzed the effect of anti-/31 mAbs or PMA on the interaction of tx4/31 with its already identified ligands (CS-1, Hep II, and VCAM-1). Similarly, although the study by Chart and Hemler (6) clearly shows changes in specificity according to the activation state of o~2/31, there are cell populations that bind laminin or/and collagen constitutively. The novelty of the present results is that mAb TS2/16 induces binding to a region of Fn (80-kD fragment) not previously identified as an ot4/31 ligand. In fact, the 80-kD fragment is a well described ligand for the ot5/31 integrin and we have extensively documented that the constitutive function of ot4/31 on leukocytes is RGD independent (12, 15, 16, 52) . The activated form of o~4/31 described here not only binds CS-1 and Hep II with high avidity, but also recognizes RGD.
Although in general a single integrin binds several ligands, ot4/31 can bind multiple and apparently quite distinct sequences within the same or different molecules. Within Fn the minimal sequences shown to be ot4/31 ligands are LDV (contained in CS-1 [26, 53] ), REDV (contained in CS-5 [34] ), and IDAPS (contained in HI [35] ). It has been proposed that the common aspartate residue on these sequences is important for o~4/31 recognition (35) . While this may be true, it is clear that other sequences may also be specific oL4/31 ligands. There is indirect evidence that the FNC/H I (YIKPGSPPREVVPRPRPGV) and FNC/H II (KNNQKS-EPLIGRKKT) peptides derived from the Hep II Fn domain (31) may also interact with ot4/31 (21) . All these sequences (CS1, CS5, HI, FNC/H I, and FNC/H II) are located in close proximity within the type M-14 repeat and the contiguous MCS region of Fn (see Fig. 1 ). Besides Fn, ot4/31 is also the receptor for VCAM-1 (9), the bacterial protein invasin (10) , and thrombospondin (55) . Although the cell-binding site(s) for some of these proteins has not been identified, it seems clear that the interaction of ct4/31 with VCAM-1 does not involve the LDV motif present on this protein (37, 51) .
The present results show that the conformational change induced in ot4/31 through the ~ subunit allows recognition of the Fn RGD sequence which is located in repeat M-10 and thus distant from the previously described a4/31 ligands. Interestingly, Koivunen et al. (24, 25) , using a phage display library, have recently identified several cyclic synthetic peptides which bind the o~5/31 integrin and do not contain the RGD motif. One of these peptides corresponds to the sequence STSDVGG which is homologous to the TVSDVPR sequence present in repeat M-10 of Fn. As noticed in that report, there is also some degree of homology with EILDVPST, a sequence present in CS-1 which we and others have shown to be a high affinity ligand for ot4/31 (16, 18, 33, 52) . Although these authors did not show direct interaction of o~5/31 with either of the two homologous sequences present in Fn, their work suggests that a5/31 has the potential to recognize other ligands in Fn besides RGD. Our present results are in agreement with a certain degree of overlapping in ligand recognition by the 0t4/31 and ot5/31 integrins. This is also supported by another report that shows that a synthetic cyclic peptide, distinct from RGD, can inhibit the function of et4/31 and o~5/31 integrins (36) . While peptide cyclation may provide an optimal ligand conformation for high affinity interactions with either ot4/31 or o~5/31, it is clear from our present study that mAb TS2/16 does not induce ot5/31 binding to the CS-1 sequence of Fn. Therefore the ability to recognize new ligands upon conformational activation may be intrinsic to the ot4/31 structure.
The present report therefore describes a novel role for ct4/31 as a receptor for the RGD site in Fn. Because t~5/31 is the classical receptor for this site we have attempted to study the contribution of c~4B1 to cell adhesion to the 80-kD Fn fragment when both integrins are expressed together. In experiments not shown, we tested whether anti-or4 mAbs could partially inhibit the binding of TS2/16-treated U937 ceils to the 80-kD fragment. However, because mAb TS2/16 also effectively upregulates the adhesion mediated by ot5B1 (1, 2, and this study), we could not detect any inhibition with mAbs anti-or4. It is possible that when c~5B1 and ot4~l are present together, o~5~1 function predominates over 0~4~/1 function in mediating adhesion to Fn. In support of this, the 80-kD fragment or the GRGD synthetic peptide completely inhibit U937 cell adhesion to Fn while the 38-kD fragment or the CS-1 peptide produce partial or no inhibition (12) . These results do not rule out a cooperation of both receptors for an efficient attachment to Fn as we have previously proposed for T lymphoid cells (15) . The results reported here are obviously important for cells which express ~4~/1 as the major surface integrin. These include B cells (16, 47) , some B cell progenitors (43) , and probably some tumor cells. Furthermore, there are reports showing different interactions with Fn during pre-B cell development (3, 50) . On ceils that express c¢5~1 besides o~4#1, properly activated a4~l may serve to cooperate with c~5~1 or to functionally replace it when ot5~l is already engaged.
It is now well documented that integrins undergo transitions among different states of activation (20) and that these transitions are induced by several agents including some mAbs as shown in the present report. The fact that the various integrin activation forms are also found in vivo, as clearly shown for o~4~1 for example (28) , suggests that activating anti-/51 mAbs (TS2/16 and others) are mimicking the effect of physiological ligands not yet identified. On the other hand, the multiplicity of sequences recognized by a4/31 must have physiological relevance. For example, it may serve to drive synergistic interactions with the receptor resulting in high affinity binding. Such synergy has already been shown for a5/31 interaction with the RGD sequence in Fn (56) . Similarly, activation of the platelet integrin cd/b/~3 with thrombin results in recognition of an additional Fn region (besides RGD) comprising part of homology repeats III-9 and HI-10 (4, see Fig. 1 ). An interesting possibility is that some of the sequences that interact with ot4/~1 may regulate o~4/31 binding to other ligands, as already shown for otIlb/33 (7) . The ot4/~l ligands described so far, including the RGD site identified in this report, apparently bind to identical or overlapping sites on t~4/31 because they are cross-inhibitory. However, it seems possible that other not yet identified ligands bind a4/31 with low affinity or at a different site, and upregulate rather than inhibit the function of ct4/31. In support of this is the fact that two Fn sequences shown to interact with ~4/~1, FNC/H I, and FNC/H II, do not (or slightly) interfere with t~4/31 adhesive function (21, 31) . The phage display library approach used for identification of ligands for ot5/~l (24, 25) may he a useful one to identify new potential ligands for ct4/~l. This would also open the possibility of using these modulatory sequences for therapeutic purposes. Moreover, because the avidity of a4/~1 for CS-1, Hep II, and RGD is different, binding to each of these sites may have different cellular consequences. Another implication of the present study is that physiologically stimulated ~4/31 may play an important role for the recruitment of lymphocytes at inflammatory sites and tissues where Fn fragments containing CS-1, Hep II, or/and RGD are produced. While these possibilities require further study, our results highlight the role of c¢4B1 as a flexible receptor able to recognize multiple ligands and support the importance of the extracellular matrix, particularly Fn, on lymphocyte development and function.
